MEI Pharma Inc
NASDAQ:MEIP
Relative Value
The Relative Value of one MEIP stock under the Base Case scenario is 10.85 USD. Compared to the current market price of 3.14 USD, MEI Pharma Inc is Undervalued by 71%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
MEIP Competitors Multiples
MEI Pharma Inc Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
US |
MEI Pharma Inc
NASDAQ:MEIP
|
20.9m USD | 0.3 | 1.1 | -2.4 | -2.4 | ||
US |
Abbvie Inc
NYSE:ABBV
|
281.3B USD | 5.2 | 58.4 | 12.7 | 19.4 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
148.1B USD | 5.3 | 22 | 16.4 | 24.5 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.8B USD | 10.5 | 28.7 | 23 | 24 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
101.7B USD | 7.8 | 25.7 | 17.2 | 18.9 | ||
AU |
CSL Ltd
ASX:CSL
|
133B AUD | 6.1 | 35.1 | 21.3 | 26.4 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
81.1B USD | 3 | 167.6 | 6.7 | 8.8 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
45.8B USD | 6.7 | -9.7 | -10.4 | -8.9 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
31.3B USD | 3.2 | 26.8 | 13.8 | 17.2 | ||
KR |
Celltrion Inc
KRX:068270
|
38.9T KRW | 17.9 | 72.5 | 44.4 | 61.1 |